JP2018531939A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531939A5
JP2018531939A5 JP2018517586A JP2018517586A JP2018531939A5 JP 2018531939 A5 JP2018531939 A5 JP 2018531939A5 JP 2018517586 A JP2018517586 A JP 2018517586A JP 2018517586 A JP2018517586 A JP 2018517586A JP 2018531939 A5 JP2018531939 A5 JP 2018531939A5
Authority
JP
Japan
Prior art keywords
compound
domain
scfv
selectively binds
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018517586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531939A (ja
JP7461620B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/055722 external-priority patent/WO2017062604A1/en
Publication of JP2018531939A publication Critical patent/JP2018531939A/ja
Publication of JP2018531939A5 publication Critical patent/JP2018531939A5/ja
Priority to JP2021196759A priority Critical patent/JP7274781B2/ja
Application granted granted Critical
Publication of JP7461620B2 publication Critical patent/JP7461620B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018517586A 2015-10-06 2016-10-06 治療用化合物及び方法 Active JP7461620B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021196759A JP7274781B2 (ja) 2015-10-06 2021-12-03 治療用化合物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237835P 2015-10-06 2015-10-06
US62/237,835 2015-10-06
PCT/US2016/055722 WO2017062604A1 (en) 2015-10-06 2016-10-06 Therapeutic compounds and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021196759A Division JP7274781B2 (ja) 2015-10-06 2021-12-03 治療用化合物及び方法

Publications (3)

Publication Number Publication Date
JP2018531939A JP2018531939A (ja) 2018-11-01
JP2018531939A5 true JP2018531939A5 (cg-RX-API-DMAC7.html) 2019-11-14
JP7461620B2 JP7461620B2 (ja) 2024-04-04

Family

ID=58488527

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018517586A Active JP7461620B2 (ja) 2015-10-06 2016-10-06 治療用化合物及び方法
JP2021196759A Active JP7274781B2 (ja) 2015-10-06 2021-12-03 治療用化合物及び方法
JP2023071386A Active JP7555625B2 (ja) 2015-10-06 2023-04-25 治療用化合物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021196759A Active JP7274781B2 (ja) 2015-10-06 2021-12-03 治療用化合物及び方法
JP2023071386A Active JP7555625B2 (ja) 2015-10-06 2023-04-25 治療用化合物及び方法

Country Status (12)

Country Link
US (4) US11098100B2 (cg-RX-API-DMAC7.html)
EP (2) EP4056190A1 (cg-RX-API-DMAC7.html)
JP (3) JP7461620B2 (cg-RX-API-DMAC7.html)
KR (1) KR102716215B1 (cg-RX-API-DMAC7.html)
CN (1) CN108697736A (cg-RX-API-DMAC7.html)
AU (2) AU2016336451B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018006811A2 (cg-RX-API-DMAC7.html)
IL (1) IL258931B (cg-RX-API-DMAC7.html)
MX (1) MX389194B (cg-RX-API-DMAC7.html)
RU (1) RU2770001C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201802794PA (cg-RX-API-DMAC7.html)
WO (1) WO2017062604A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220890T1 (hr) 2015-02-06 2022-10-14 National University Of Singapore Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
JP7461620B2 (ja) 2015-10-06 2024-04-04 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 治療用化合物及び方法
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3511340B1 (en) 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CA3071282A1 (en) 2017-08-10 2019-02-14 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11795226B2 (en) 2017-12-12 2023-10-24 Macrogenics, Inc. Bispecific CD16-binding molecules and their use in the treatment of disease
CU24545B1 (es) * 2017-12-29 2021-09-07 Ct Ingenieria Genetica Biotecnologia Péptido antagonista de la actividad de la interleucina-15
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210017277A1 (en) * 2018-03-14 2021-01-21 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Anti-cd33 chimeric antigen receptors and their uses
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN112912400B (zh) * 2018-10-19 2025-05-30 明尼苏达大学董事会 Nk接合子分子及其使用方法
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
WO2020172598A1 (en) * 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
US12565658B2 (en) 2019-05-31 2026-03-03 City Of Hope CD33 targeted chimeric antigen receptor modified T cells for treatment of CD33 positive malignancies
IL288713B2 (en) * 2019-06-12 2026-01-01 Univ Leland Stanford Junior Methods for treating viral infections
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
BR112022004712A2 (pt) * 2019-09-16 2022-06-14 Gt Biopharma Inc Compostos e métodos de imunoterapia
BR112022005666A2 (pt) * 2019-09-26 2022-06-21 Univ Minnesota Compostos engatadores de nk que se ligam a antígenos virais e métodos de uso
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP4084821A4 (en) * 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
AU2021260960A1 (en) 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
CA3183711A1 (en) * 2020-06-03 2021-12-09 Regents Of The University Of Minnesota B7h3-targeting proteins and methods of use thereof
WO2022150379A1 (en) * 2021-01-08 2022-07-14 Regents Of The University Of Minnesota Nk cell engager molecules and methods of use
US20250206823A1 (en) 2021-07-30 2025-06-26 Qure Biotechnology (Shanghai) Co., Ltd. Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereof
WO2023036270A1 (zh) 2021-09-09 2023-03-16 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CN118201961A (zh) * 2021-09-16 2024-06-14 Gt生物制药公司 Pd-l1靶向融合蛋白及其使用方法
US20250319128A1 (en) * 2022-05-16 2025-10-16 Northwestern University Il15-modified car t cells for dual targeting
CA3253069A1 (en) * 2022-05-31 2023-12-07 Oncopeptides Innovation 1 Ab NEW POLYPEPTIDES
EP4587122A1 (en) 2022-09-15 2025-07-23 Avidicure IP B.V. Multispecific antigen binding proteins for stimulating nk cells and use thereof
WO2024064446A2 (en) * 2022-09-19 2024-03-28 Duke University Compositions and methods for the enhancement of immune cell activities against cancer
CN118909134A (zh) * 2023-05-06 2024-11-08 北京新合睿恩生物医疗科技有限公司 IL-15融合蛋白及其mRNA序列和应用
CN121773132A (zh) * 2023-05-12 2026-03-31 克里斯蒂安-阿尔伯特基尔大学 用于扩增nk细胞的手段和方法
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191139A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
CN100473664C (zh) * 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途
RS20050481A (sr) 2002-12-20 2007-08-03 Biogen Idec Ma Inc., Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima
HUE033129T2 (en) 2003-07-24 2017-11-28 Innate Pharma Sa Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CN1838965B (zh) * 2004-03-19 2011-07-06 森永乳业株式会社 用于癌症治疗的药品
EP2322560B1 (en) * 2005-03-10 2013-09-04 Morphotek, Inc. Anti-mesothelin antibodies
EP2046375B1 (en) 2006-07-20 2017-04-05 The General Hospital Corporation Methods and compositions for the selective activation of protoxins through combinatorial targeting
CN101657719A (zh) 2007-01-26 2010-02-24 路易斯维尔大学研究基金会公司 检测用于诊断和表征障碍的自身抗体的方法
US9155798B2 (en) 2007-08-24 2015-10-13 Regents Of The University Of Minnesota Receptor-targeting reagents containing epidermal factor receptor-binding agents and IL-13 receptor-binding agents or IL-4 receptor-binding agents
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
EP2245153A4 (en) 2008-02-13 2011-06-22 Dyax Corp IMPROVED METHODS FOR PRODUCING SPECIFIC BINDING SAVINGS
EP2332994A1 (en) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP5316719B2 (ja) 2010-08-03 2013-10-16 富士通株式会社 検証プログラムおよび検証装置
JP6251570B2 (ja) 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体il−15可溶性融合分子並びにその製造及び使用方法
CN102251013A (zh) * 2011-02-22 2011-11-23 北京市肿瘤防治研究所 一个识别肿瘤起始细胞的抗体和抗原及其应用
EP2714735B1 (en) * 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
WO2013039883A1 (en) * 2011-09-12 2013-03-21 Abbvie Biotherapeutics Inc. Artificial nk cells and uses thereof
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
CN104640561A (zh) 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
US9537609B2 (en) * 2012-08-02 2017-01-03 International Business Machines Corporation Storing a stream of data in a dispersed storage network
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
US20160015749A1 (en) * 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
US9879081B2 (en) * 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
CA2953816C (en) 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
JP7461620B2 (ja) 2015-10-06 2024-04-04 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 治療用化合物及び方法
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3457139B1 (en) 2017-09-19 2026-08-05 Promise Proteomics Antibody-like peptides for quantifying therapeutic antibodies
US11951129B2 (en) 2018-01-09 2024-04-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compositions and methods for targeting CLEC12A-expressing cancers

Similar Documents

Publication Publication Date Title
JP2021515806A5 (cg-RX-API-DMAC7.html)
CY1124090T1 (el) Συνθεσεις αντισωματων για τη θεραπεια ογκων
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
IL256871B2 (en) Constructs for bispecific antibodies binding dll3 and cd3 and uses thereof
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
JP2017114866A5 (cg-RX-API-DMAC7.html)
JP2018052979A5 (cg-RX-API-DMAC7.html)
FI3348571T3 (fi) Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini
MY205343A (en) Anti-muc1 antibody
JP2015527366A5 (cg-RX-API-DMAC7.html)
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
JP2017506649A5 (cg-RX-API-DMAC7.html)
CN111615521A (zh) 抗pd-l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备
JP2012519492A5 (cg-RX-API-DMAC7.html)
ES2570131T3 (es) Ratones que expresan una cadena ligera de inmunoglobulina híbrida
MX2021003636A (es) Receptor antigenico quimerico.
JP2017504578A5 (cg-RX-API-DMAC7.html)
PE20091024A1 (es) Anticuerpos monoclonales que se unen a anexelekto y sus usos
FI3981792T3 (fi) Pd-1:tä sitovia molekyylejä ja niiden käyttömenetelmiä
TR201910814T4 (tr) Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
IN2014MN02293A (cg-RX-API-DMAC7.html)
EP4364809A3 (en) Cd19 specific chimeric antigen receptor and uses thereof
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
HRP20220133T1 (hr) Optimizirana anti-cd3 bispecifična antitijela i njihove upotrebe